• Thomás Cavalcanti Pires de Azevedo, Pedro Vianna de Freitas, Pedro Henrique Padilha da Cunha, Eraldo Abillio Pereira Moreira, Thiago José Matos Rocha, Fabiano Timbó Barbosa, Célio Fernando de Sousa-Rodrigues, and RamosFernando Wagner da SilvaFWDShttp://orcid.org/0000-0002-5277-4759Centro Universitário Cesmac - Maceió (AL), Brazil.Universidade Estadual de Ciências da Saúde de Alagoas - Maceió (AL), Brazil.Secretaria de Estado da Saúde de Alagoas - Maceió (AL), Braz.
• Centro Universitário Cesmac - Maceió (AL), Brazil.
• Rev Assoc Med Bras (1992). 2021 Jan 1; 67 (3): 474-478.

IntroductionThe rapid advance of Coronavirus disease 2019 (Covid-19) has led to the incessant search for therapeutic and prophylactic measures to fight the pandemic. Because it is a viral infection, the safest long-term prophylactic form, in addition to social distance and hygiene, is the vaccine.ObjectiveThus, this study aimed at conducting a review of the efficacy and landscape of Covid-19 vaccines.MethodsThe following electronic databases were used MEDLINE via PubMed, SCIELO, LILACS, NEJM, and Clinical Trials. Our study includes the 7 vaccines (phase 3) that reported an efficacy rate for Covid-19, including characteristics inherent to each one of them.ResultsPreliminary studies have shown that, although an efficacy ≥70% is necessary to eliminate the infection, a prophylactic vaccine with efficacy <70% will still have an important impact and can contribute to the elimination of the virus, provided that appropriate measures of social distancing remain.ConclusionsThe effectiveness of the vaccines obtained in this study varied between 50.38 and 95%, data that may represent a reduction in serious cases, hospitalizations, sequels, and deaths caused by Covid-19, respecting the panorama presented in this article.

6 keywords...

hide…